Dr. Barkoudah is a member of the Brigham Health Hospital Medicine Unit in the Department of Medicine. Dr. Barkoudah is the Associate Director of Hospital Medicine Unit and a Medical Director.
Dr. Barkoudah research interest lies in clinical research outcomes as well as clinical trials of therapeutic interventions through his role in the Clinical Endpoint Center at the Brigham and Womens Hospital.
His work focuses on quality improvement and clinical innovation. He currently serves on several clinical innovations committees, at Brigham and Womens Healthcare and Partners Healthcare.
After serving as a post-doctoral research fellow in physiology, Dr. Barkoudah completed his residency in Internal Medicine and Pediatrics at the University of Tennessee Health Science Center.
He served as an assistant in medicine at the Massachusetts General Hospital, then joined the General Medicine Division at Brigham and Womens Hospital as Associate Physician, and Harvard Medical School as Assistant Professor.
He has also earned a Master degree in Public Health (MPH) from Harvard T.H. Chan School of Public Health.
- McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
- Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-92.
- Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA. 2013;309(11):1125-35.
- Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med. 2013;368(13):1210-9.
- Pouleur AC, Barkoudah E, Uno H, Skali H, Finn PV, Zelenkofske SL, et al. Pathogenesis of sudden unexpected death in a clinical trial of patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. Circulation. 2010;122(6):597-602.
- McMurray JJ, Krum H, Abraham WT, Dickstein K, Køber LV, Desai AS, et al. Aliskiren, Enalapril, or Aliskiren and Enalapril in Heart Failure. N Engl J Med. 2016;374(16):1521-32.
- Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, et al. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize Outcomes in Patients with Heart failure (ATMOSPHERE) study. Eur J Heart Fail. 2011;13(1):107-14.
- Kristensen SL, Preiss D, Jhund PS, Squire I, Cardoso JS, Merkely B, et al. Risk Related to Pre-Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction: Insights From Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial. Circ Heart Fail. 2016;9(1).
- McMurray JJ, Anand IS, Diaz R, Maggioni AP, O'Connor C, Pfeffer MA, et al. Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. Eur J Heart Fail. 2009;11(8):795-801.
- Gheorghiade M, Albaghdadi M, Zannad F, Fonarow GC, Böhm M, Gimpelewicz C, et al. Rationale and design of the multicentre, randomized, double-blind, placebo-controlled Aliskiren Trial on Acute Heart Failure Outcomes (ASTRONAUT). Eur J Heart Fail. 2011;13(1):100-6.
